NEWSLETTER

By clicking submit, you agree to share your email address with TFN to receive marketing, updates, and other emails from the site owner. Use the unsubscribe link in the emails to opt out at any time.

Sanofi acquires UK-based Vicebio for up to $1.6B to develop next-gen respiratory vaccine

PhaSER Biomedical wins a $2.3 M Grant to strengthen global health drug discovery efforts

French pharmaceutical giant Sanofi has acquired UK-based vaccine developer Vicebio for up to $1.6 billion, comprising an upfront payment of $1.15 billion plus an additional $450 million tied to development and regulatory milestones. The transaction is subject to customary closing conditions, including regulatory approvals, and is expected to close in the fourth quarter of 2025.

This acquisition underscores Sanofi’s sharpened focus on infectious disease prevention and expands its capabilities with innovative vaccine technologies poised to address growing global health challenges.

A strategic investment in respiratory health

Sanofi’s acquisition of Vicebio, a biopharma startup headquartered in London, brings significant technological and clinical assets into its portfolio. The transaction includes an upfront payment of $1.15 billion, with an additional $450 million tied to development and regulatory milestones. This investment signals Sanofi’s commitment to advancing next-generation vaccines, particularly against respiratory viral infections that remain major causes of illness and death worldwide.

Venture firm Medicxi founded Vicebio and has attracted backing from prominent life sciences investors, including TCGX, Goldman Sachs Alternatives, Avoro Ventures, and venBio Partners. Their support was most recently demonstrated in a Series B round announced in 2024, which aimed to accelerate Vicebio’s clinical pipeline.

The deal complements Sanofi’s established position in the respiratory vaccines sector, where it currently offers products for flu and RSV prevention. Vicebio’s pipeline adds a non-mRNA vaccine option for RSV and human metapneumovirus (hMPV), expanding physician and patient choices.

The Molecular Clamp technology

At the heart of the acquisition lies Vicebio’s proprietary Molecular Clamp technology, a breakthrough platform originally developed at The University of Queensland. This technology allows scientists to stabilise viral glycoproteins, structures on the surface of viruses that trigger immune responses. By maintaining these proteins in their pre-fusion state, their most immunologically potent form, the Molecular Clamp helps vaccines generate stronger and longer-lasting protection.

Importantly, the Molecular Clamp also facilitates the high-yield production of liquid multivalent vaccines, allowing multiple viral targets to be addressed in a single formulation. This opens the door to scalable, ready-to-use vaccines that could simplify immunisation logistics and enhance global response efforts during viral outbreaks.

A lead candidate tackling RSV and hMPV

Among the most promising assets Sanofi gains through this acquisition is VXB-241, Vicebio’s lead vaccine candidate. This bivalent vaccine targets two serious respiratory pathogens: Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV). Both viruses are known to cause severe illness in older adults and immunocompromised individuals, with few effective vaccines currently available on the market.

VXB-241 is currently undergoing exploratory Phase 1 trials, with early results showing a favourable safety and tolerability profile in adults aged 60 and over. These findings support continued clinical development and suggest that the vaccine may one day offer much-needed protection to vulnerable populations.

Expanding vaccine pipeline

For Sanofi, this acquisition of Vicebio led by Emmanuel Hanon represents a move to diversify and deepen its vaccine research and development capabilities. Respiratory viruses such as RSV, hMPV, and emerging coronaviruses remain persistent threats. Vicebio’s technology provides Sanofi with a flexible platform that can be adapted to a broad range of viral targets, allowing rapid response to future outbreaks or unmet medical needs.

The addition of the Molecular Clamp platform could also enhance Sanofi’s ability to develop multivalent vaccines, which are increasingly viewed as essential tools for efficient public health campaigns. As the global vaccine market continues to evolve post-pandemic, pharmaceutical players are seeking adaptable platforms and robust pipelines and Vicebio delivers on both fronts.

Looking ahead

As respiratory viruses remain a pressing health concern, particularly in aging populations, Sanofi’s acquisition of Vicebio positions it at the forefront of vaccine innovation. By integrating Vicebio’s proprietary platform and clinical pipeline, Sanofi strengthens its long-term strategy to prevent infectious diseases and respond swiftly to viral threats.

While VXB-241’s clinical journey is still in its early stages, the broader implications of the acquisition are clear. With scalable technology, strong early data, and a strategic fit within Sanofi’s vaccine division, the Vicebio deal could shape the next chapter in respiratory disease prevention.

Dr. Giovanni Mariggi, Chairman of Vicebio and Partner at Medicxi, said: “Our aim in creating Vicebio was to back a clear product vision to develop a best-in-class vaccine against respiratory viruses. We are extremely proud of what we have accomplished in the last few years thanks to a team effort by the Company, University of Queensland, our investors and the Board. We are excited to partner with Sanofi which will further accelerate VXB-241’s development to ensure it ultimately benefits those in need.”  

Cariad Chester, Managing Partner at TCGX said: “Vicebio has successfully developed best-in-class multivalent vaccines targeting leading causes of respiratory disease. These vaccines have the potential to protect millions of patients from life-threatening viral infections and we are thrilled to partner with Sanofi to accelerate their development. We look forward to working with Sanofi and combining our innovative technology with Sanofi’s global clinical development capability.”  

Dr. Emmanuel Hanon, Chief Executive Officer of Vicebio, added: “Vicebio and its incredibly passionate team have been driven by the ambition to develop next-generation vaccines aimed at targeting multiple life-threatening respiratory viruses simultaneously. This acquisition validates our ability to combine innovation and deep scientific expertise towards a common goal of advancing public health prevention, and we’re excited to enter the next chapter to accelerate the global impact of our work.”

Total
0
Shares
Related Posts
Total
0
Share
tfn-logo-2-220x220-removebg-preview

Get daily funding news briefings in the tech world delivered right to your inbox.

Enter Your Email
join our newsletter. thank you
TFN Banner